|2007||Immunovia AB is founded in 2007 by researchers at the Department of Immunology at Lund University and CREATE Health – Center for Translational Cancer Research, in Lund, Sweden.
The purpose is to commercialize discoveries and patents held in human antibodies, biomarkers and antibody arrays.
|2007-2013||The antibody platform technology is further developed and a number of important patents are submitted.
Clinical trials and multicenter studies in Spain regarding pancreatic cancer diagnosis are conducted.
|2014 -2015||Immunovia carries out a new issue of approximately 43 MSEK and receives Horizon 2020 allocations of approximately 43 MSEK over two years.
Several important clinical studies are conducted, including a study in China showing that the pancreatic signature works in populations with different genetic background.
First data on the early diagnosis of asymptomatic stage I and II pancreatic cancer are encouraging / positive.
Immunovia is listed on Nasdaq First North and in connection with this, approximately 60 MSEK is generated, excluding transaction costs.
|2016||The company carries out a rights issue and a directed issue of approximately 29 MSEK and 190 MSEK excluding transaction costs.
Collaboration agreements on prospective studies in PanFAM-1 are signed with various research centers, including Mount Sinai, New York, USA and the Ramon and Cajal Institute for Health Research, Madrid.
Immunovia receives the “2016 Stars of Innovation Prize” for most Innovative SME in Europe.
A Letter of Intent is signed with the National Cancer Institute (NCI) in the United States stating that Immunovia will be part of NCI’s program for the pancreatic cancer risk group New Onset Diabetes type II (NOD) over 50 years of age.
|The NCI project in NOD-associated pancreatic cancer is delayed due to budget problems at NCI, which also changes the focus of the program.
The world’s largest prospective study of the largest risk group for pancreatic cancer is initiated; People Over 50 Years Getting Their First Diagnosis of Diabetes type II (PanDIA-1).
The prospective study for familiar/hereditary pancreatic cancer (“PanFAM-1”) is expanded to include the Mount Sinai in New York, the Knight Cancer Institute at Oregon Health and Sciences University, Portland, USA, University of Liverpool, UK, Ramon y Cajal Institute for Health Research, Madrid, Spain, Sahlgrenska University Hospital, Gothenburg, and University of Pittsburgh, USA.
Immunovia’s study in autoimmunity shows that SLE can be distinguished from three other common autoimmune diseases with similar symptoms, including Rheumatoid arthritis.
The company has to postpone the scheduled sales start-up to the second half of 2018, because of an increased need for industrialization and accreditation activities, partly due to increased requirements in an updated ISO 13485 standard.
Start of prospective patient sample collection at the University College London Hospital. Patients with early symptoms that may be pancreatic cancer are collected, led by Professor Steve Pereira, one of the world’s leading Key Opinion Leaders in this risk group (PanSYM-1).
Immunovia receives a contribution of SEK 4.9 million from SWElife.
Excellent results from the study regarding differential diagnosis of autoimmune diseases including SLE, RA, Vasculitis and Sjögren’s syndrome are obtained.
A collaboration agreement is signed with Linköping University Hospital that gives Immunovia access to biobanks in SLE, RA, Vasculitis and Sjögren’s Syndrome for follow-up and supplementary retrospective studies.
Establishment of US office for the subsidiary Immunovia Inc., with its own reference laboratory in Boston.